SOP Guide for Pharma

Analytical Method Development: Use of Design of Experiments (DoE) in Method Development – V 2.0

Analytical Method Development: Use of Design of Experiments (DoE) in Method Development – V 2.0

SOP for Applying Design of Experiments (DoE) in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/017/2025
Supersedes SOP/AMD/017/2022
Page No. Page 1 of 15
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP provides a systematic approach for the application of Design of Experiments (DoE) in analytical method development. It aims

to identify critical method parameters (CMPs), understand their impact on method performance, and facilitate robust, reproducible, and scientifically justified method design in line with ICH Q8, Q9, and Q14 guidelines.

2. Scope

This SOP applies to all method development activities involving chromatographic, spectroscopic, and physicochemical analytical techniques within the Analytical Method Development (AMD) department where DoE is employed to optimize and characterize analytical methods.

3. Responsibilities

  • Analytical Scientist: Designs and executes the DoE, interprets results, and identifies MODR.
  • Statistician/Design Expert: Provides guidance on model selection, software usage, and statistical analysis.
  • Team Lead: Reviews DoE strategy, study results, and performance metrics.
  • QA: Verifies compliance with documentation and regulatory standards.
  • Head – AMD: Approves DoE-based development conclusions and MODR definition.

4. Accountability

The Head of AMD is accountable for ensuring DoE principles are correctly applied and documented during analytical method development, enabling robust and compliant method lifecycle management.

5. Procedure

5.1 DoE Planning and Strategy

  1. Define the objective of DoE (e.g., optimization, screening, robustness).
  2. Select appropriate design:
    • Screening: Plackett-Burman, Full Factorial
    • Optimization: Central Composite Design (CCD), Box-Behnken
    • Robustness: Fractional Factorial, Taguchi
  3. Document the design plan using Annexure-1: DoE Design Summary.

5.2 Selection of Factors and Levels

  1. Identify method parameters to be studied (e.g., pH, flow rate, column temperature, mobile phase composition).
  2. Define levels (minimum, center, maximum) based on historical data or feasibility trials.
  3. Record all inputs in Annexure-2: DoE Factor Table.

5.3 Execution of Experimental Runs

  1. Perform experimental runs as per DoE matrix using validated instruments.
  2. Ensure sample prep, injection volume, and detection are consistent across runs.
  3. Monitor key responses (e.g., retention time, resolution, tailing, %RSD).
  4. Capture output in Annexure-3: DoE Experimental Log.

5.4 Statistical Analysis and Model Interpretation

  1. Analyze data using statistical software (e.g., Design-Expert, Minitab, JMP).
  2. Generate response surface plots, interaction plots, and contour plots.
  3. Determine significance using ANOVA (p-value < 0.05), model R², lack of fit.
  4. Identify CMPs and estimate optimal region (MODR).
  5. Summarize findings in Annexure-4: DoE Statistical Summary.

5.5 Verification of Optimal Conditions

  1. Confirm method performance at optimal DoE-predicted settings.
  2. Conduct replicate runs and compare with predicted values.
  3. If within acceptable error range, lock the method parameters.
  4. Report verification results in Annexure-5: DoE Verification Record.

5.6 Documentation and Approval

  1. Compile all DoE-related annexures and include in Method Development Report.
  2. Obtain QA and HOD approval before proceeding to validation.
  3. Store raw data and software files in designated servers with version control.

6. Abbreviations

  • DoE: Design of Experiments
  • MODR: Method Operable Design Region
  • CMP: Critical Method Parameter
  • RSD: Relative Standard Deviation
  • Rs: Resolution
  • QA: Quality Assurance

7. Documents

  1. DoE Design Summary – Annexure-1
  2. DoE Factor Table – Annexure-2
  3. DoE Experimental Log – Annexure-3
  4. DoE Statistical Summary – Annexure-4
  5. DoE Verification Record – Annexure-5

8. References

  • ICH Q8(R2) – Pharmaceutical Development
  • ICH Q9 – Quality Risk Management
  • ICH Q14 – Analytical Procedure Development
  • USP General Chapter <1032> – Design and Analysis of Biological Assays

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: DoE Design Summary

DoE Type Objective Software Used Date
Central Composite Optimization of assay method Design-Expert v13 12/05/2025

Annexure-2: DoE Factor Table

Factor Low Center High Unit
Flow Rate 0.8 1.0 1.2 mL/min
pH 2.5 3.0 3.5 pH Units

Annexure-3: DoE Experimental Log

Run Flow Rate pH RT (min) Rs Tailing
1 1.0 3.0 7.8 2.1 1.1

Annexure-4: DoE Statistical Summary

Response Adj R² p-value Lack of Fit
Rs 0.964 0.951 <0.0001 Not Significant

Annexure-5: DoE Verification Record

Parameter Predicted Observed Deviation (%) Status
Rs 2.0 1.95 2.5% Accepted

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Added statistical annexures and verification log ICH Q14 alignment
Exit mobile version